Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on (ARWR) On The My Stocks Page - news.stocktradersdaily.com

(ARWR) On The My Stocks Page  news.stocktradersdaily.com

(ARWR) On The My Stocks Page - news.stocktradersdaily.com

Click here to get full coverage on Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Yahoo Finance

Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential  Yahoo Finance

Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Yahoo Finance

Click here to get full coverage on Arrowhead Pharmaceuticals Is Finally Arriving (NASDAQ:ARWR) - Seeking Alpha

Arrowhead Pharmaceuticals Is Finally Arriving (NASDAQ:ARWR)  Seeking Alpha

Arrowhead Pharmaceuticals Is Finally Arriving (NASDAQ:ARWR) - Seeking Alpha

Click here to get full coverage on Arrowhead Pharma Taps Walgreens Finance Chief to Lead Commercial Stage Transition - Stock Titan

Arrowhead Pharma Taps Walgreens Finance Chief to Lead Commercial Stage Transition  Stock Titan

Arrowhead Pharma Taps Walgreens Finance Chief to Lead Commercial Stage Transition - Stock Titan

Click here to get full coverage on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 69% of the company - simplywall.st

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 69% of the company  simplywall.st

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 69% of the company - simplywall.st

Click here to get full coverage on Arrowhead Pharmaceuticals Inc. (ARWR) reports earnings - Quartz

Arrowhead Pharmaceuticals Inc. (ARWR) reports earnings  Quartz

Arrowhead Pharmaceuticals Inc. (ARWR) reports earnings - Quartz

Click here to get full coverage on Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - Business Wire

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences  Business Wire

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - Business Wire

Click here to get full coverage on Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - Insider Monkey

Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money”  Insider Monkey

Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - Insider Monkey

Click here to get full coverage on Arrowhead (ARWR) Advances Phase 3 Trials for Plozasiran | ARWR S - GuruFocus

Arrowhead (ARWR) Advances Phase 3 Trials for Plozasiran | ARWR S  GuruFocus

Arrowhead (ARWR) Advances Phase 3 Trials for Plozasiran | ARWR S - GuruFocus

Click here to get full coverage on Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - Yahoo Finance

Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money”  Yahoo Finance

Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - Yahoo Finance

Click here to get full coverage on Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry  simplywall.st

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st

Click here to get full coverage on Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) (ARWR) - Seeking Alpha

Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) (ARWR)  Seeking Alpha

Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) (ARWR) - Seeking Alpha

Click here to get full coverage on Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ... - Yahoo Finance

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ...  Yahoo Finance

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ... - Yahoo Finance

Click here to get full coverage on Insiders Could Have Profited By Holding onto Arrowhead Pharmaceuticals Shares Despite 23% Drop - simplywall.st

Insiders Could Have Profited By Holding onto Arrowhead Pharmaceuticals Shares Despite 23% Drop  simplywall.st

Insiders Could Have Profited By Holding onto Arrowhead Pharmaceuticals Shares Despite 23% Drop - simplywall.st

Click here to get full coverage on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company - Yahoo Finance

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company  Yahoo Finance

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company - Yahoo Finance

Click here to get full coverage on Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ... - Yahoo Finance

Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ...  Yahoo Finance

Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ... - Yahoo Finance

Click here to get full coverage on ARWR: Multiple Value Drivers for Long-Term Growth… - Yahoo Finance

ARWR: Multiple Value Drivers for Long-Term Growth…  Yahoo Finance

ARWR: Multiple Value Drivers for Long-Term Growth… - Yahoo Finance

Click here to get full coverage on Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results - Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results  Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results - Business Wire

Click here to get full coverage on Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal - Investor's Business Daily

Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal  Investor's Business Daily

Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal - Investor's Business Daily

Click here to get full coverage on Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR) - Seeking Alpha

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR)  Seeking Alpha

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR) - Seeking Alpha

Click here to get full coverage on ARWR July 18th Options Begin Trading - Nasdaq

ARWR July 18th Options Begin Trading  Nasdaq

ARWR July 18th Options Begin Trading - Nasdaq

Click here to get full coverage on Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study - Insider Monkey

Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study  Insider Monkey

Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study - Insider Monkey

Click here to get full coverage on Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran - Business Wire

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran  Business Wire

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran - Business Wire

Click here to get full coverage on Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results - Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results  Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results - Business Wire

Click here to get full coverage on With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners - Yahoo Finance

With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners  Yahoo Finance

With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners - Yahoo Finance

Click here to get full coverage on Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences | ARWR Stock News - GuruFocus

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences | ARWR Stock News  GuruFocus

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences | ARWR Stock News - GuruFocus

Click here to get full coverage on Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ... - Yahoo Finance

Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ...  Yahoo Finance

Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ... - Yahoo Finance

Click here to get full coverage on SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - Seeking Alpha

SA analyst downgrades: PLTR, PSTG, NTLA, ARWR  Seeking Alpha

SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - Seeking Alpha

Click here to get full coverage on Why Arrowhead Pharmaceuticals (ARWR) is Poised for Breakout Growth in 2025 and Beyond - AInvest

Why Arrowhead Pharmaceuticals (ARWR) is Poised for Breakout Growth in 2025 and Beyond  AInvest

Why Arrowhead Pharmaceuticals (ARWR) is Poised for Breakout Growth in 2025 and Beyond - AInvest

Click here to get full coverage on Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran | ARWR Stock News - GuruFocus

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran | ARWR Stock News  GuruFocus

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran | ARWR Stock News - GuruFocus

Click here to get full coverage on Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Business Wire

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)  Business Wire

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Business Wire

Click here to get full coverage on UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News - GuruFocus

UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News  GuruFocus

UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News - GuruFocus

Click here to get full coverage on Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity - Business Wire

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity  Business Wire

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity - Business Wire

Click here to get full coverage on Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - Yahoo Finance

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases  Yahoo Finance

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - Yahoo Finance

Click here to get full coverage on Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey

Top 11 Small Cap Stocks to Buy with Biggest Upside Potential  Insider Monkey

Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey

Click here to get full coverage on Arrowhead (ARWR) Advances on New Drug Development and Strategic Funding | ARWR Stock News - GuruFocus

Arrowhead (ARWR) Advances on New Drug Development and Strategic Funding | ARWR Stock News  GuruFocus

Arrowhead (ARWR) Advances on New Drug Development and Strategic Funding | ARWR Stock News - GuruFocus

Click here to get full coverage on Arrowhead's Rare Disease Drug Plozasiran Gets FDA Review After Strong Phase 3 Results - Stock Titan

Arrowhead's Rare Disease Drug Plozasiran Gets FDA Review After Strong Phase 3 Results  Stock Titan

Arrowhead's Rare Disease Drug Plozasiran Gets FDA Review After Strong Phase 3 Results - Stock Titan

Click here to get full coverage on Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results - Business Wire

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results  Business Wire

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results - Business Wire

Click here to get full coverage on Arrowhead stock holds Buy rating, $80 target from H.C. Wainwright - Investing.com

Arrowhead stock holds Buy rating, $80 target from H.C. Wainwright  Investing.com

Arrowhead stock holds Buy rating, $80 target from H.C. Wainwright - Investing.com

Click here to get full coverage on Arrowhead stock hits 52-week low at $14.21 amid market challenges - Investing.com

Arrowhead stock hits 52-week low at $14.21 amid market challenges  Investing.com

Arrowhead stock hits 52-week low at $14.21 amid market challenges - Investing.com

Click here to get full coverage on Earnings call transcript: Arrowhead Pharmaceuticals’ Q2 2025 Surpasses Forecasts - Investing.com

Earnings call transcript: Arrowhead Pharmaceuticals’ Q2 2025 Surpasses Forecasts  Investing.com

Earnings call transcript: Arrowhead Pharmaceuticals’ Q2 2025 Surpasses Forecasts - Investing.com

Click here to get full coverage on Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus

Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News  GuruFocus

Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus

Click here to get full coverage on Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns - Seeking Alpha

Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns  Seeking Alpha

Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns - Seeking Alpha

Click here to get full coverage on Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases - Business Wire

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases  Business Wire

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases - Business Wire

Click here to get full coverage on Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer - Business Wire

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer  Business Wire

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer - Business Wire

Click here to get full coverage on Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - Benzinga

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases  Benzinga

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - Benzinga

Click here to get full coverage on Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics - Business Wire

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics  Business Wire

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics - Business Wire

Click here to get full coverage on Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity  Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - Business Wire

Click here to get full coverage on Cantor Fitzgerald maintains Overweight on Arrowhead stock - Investing.com

Cantor Fitzgerald maintains Overweight on Arrowhead stock  Investing.com

Cantor Fitzgerald maintains Overweight on Arrowhead stock - Investing.com

Click here to get full coverage on Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs - Business Wire

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs  Business Wire

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs - Business Wire

Click here to get full coverage on SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - MSN

SA analyst downgrades: PLTR, PSTG, NTLA, ARWR  MSN

SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - MSN

Click here to get full coverage on Citi cuts Arrowhead stock target to $17, maintains neutral - Investing.com

Citi cuts Arrowhead stock target to $17, maintains neutral  Investing.com

Citi cuts Arrowhead stock target to $17, maintains neutral - Investing.com

Click here to get full coverage on Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity  Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - Business Wire

Click here to get full coverage on Arrowhead Pharmaceuticals Stock Dips Despite Promising Study - TipRanks

Arrowhead Pharmaceuticals Stock Dips Despite Promising Study  TipRanks

Arrowhead Pharmaceuticals Stock Dips Despite Promising Study - TipRanks

Click here to get full coverage on Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results - Yahoo Finance

Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results  Yahoo Finance

Arrowhead Pharmaceuticals Inc (ARWR)

Price Chart

Key Statistics

Technicals

About ARWR

Latest News

(ARWR) On The My Stocks Page - news.stocktradersdaily.com

Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Yahoo Finance

Arrowhead Pharmaceuticals Is Finally Arriving (NASDAQ:ARWR) - Seeking Alpha

Advanced Charts

Top Gainers

Top Losers